Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
76 participants
INTERVENTIONAL
2025-08-19
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
NCT07307274
A Study to Evaluate the Safety and Tolerability of ILB-202
NCT05843799
A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects
NCT04532957
Safety and Tolerability Study of ARC-520 in Healthy Volunteers
NCT01872065
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
NCT04485481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SAD Cohort 1
SAD dose 1
YP05002
Tablet, QD
Placebo
Tablet, QD
SAD Cohort 2
SAD dose 2
YP05002
Tablet, QD
Placebo
Tablet, QD
SAD Cohort 3
SAD dose 3
YP05002
Tablet, QD
Placebo
Tablet, QD
SAD Cohort 4
SAD dose 4
YP05002
Tablet, QD
Placebo
Tablet, QD
SAD Cohort 5
SAD dose 5
YP05002
Tablet, QD
Placebo
Tablet, QD
MAD Cohort 1
MAD dose 1
YP05002
Tablet, QD
Placebo
Tablet, QD
MAD Cohort 2
MAD dose 2
YP05002
Tablet, QD
Placebo
Tablet, QD
MAD Cohort 3
MAD dose 3
YP05002
Tablet, QD
Placebo
Tablet, QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YP05002
Tablet, QD
Placebo
Tablet, QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy male and female participants aged 18-65 years (both inclusive).No restrictions on race.
3. In good health as determined by the Investigator, with no clinically significant findings from medical/psychiatric history, physical examination, 12-lead ECG, vital signs measurements, clinical laboratory evaluations.
Exclusion Criteria
2. Histories of using drug that affect drug absorption, distribution, metabolism, or excretion within 14 days or within 5-half-life prior to the first dose (whichever is longer); gastrointestinal disorders with impaired gastric emptying; or prolonged use of medications that directly modulate gastrointestinal motility.
3. Had clinically relevant acute or chronic medical conditions or diseases that would pose a risk to participant's safety or interfere with the study assessments, as determined by the Investigator.
4. Any malignancy (except basal cell carcinoma and squamous cell carcinoma of the skin) in the previous 5 years.
5. Diagnosis of any type of pancreatitis.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yaopharma Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nucleus Network Melbourne Clinic
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YP05002-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.